Helus Pharma Partners with TARA Mind to Boost HLP003 Phase 3 Veteran Trial Recruitment Under Trump Order
Helus Pharma teamed with TARA Mind and VETS to boost recruitment for its HLP003 Phase 3 major depressive disorder trial in veteran communities. The partnership leverages President Trump’s April 18 Executive Order on serious mental illness treatments to expand clinical research participation among veterans.
1. Partnership Overview
Helus Pharma has launched a collaboration with TARA Mind and Veterans Exploring Treatment Solutions to support its PARADIGM HLP003 Phase 3 major depressive disorder trial. The program, featuring Helus’s Breakthrough Therapy-designated NSA candidate HLP003, aims to enhance mental health treatment options for veterans through structured clinical research participation.
2. Veteran Recruitment Strategy
TARA Mind and VETS will deploy their clinician-guided collaborative care platform and veteran networks to facilitate targeted outreach, education, and enrollment in the Phase 3 trial. This approach focuses on increasing trial access among veterans facing high rates of depression, PTSD, and suicide risk.
3. Regulatory Alignment
The initiative aligns with the April 18 Executive Order on Accelerating Medical Treatments for Serious Mental Illness, which prioritizes expanding innovative research for underserved populations, including veterans. The partnership is expected to streamline recruitment and support timely progression through regulatory milestones for HLP003.